Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | METAP2 | P50579 | 2/20 | 0.41 |
| ▸ | SLC1A3 | P43003 | 3/20 | 0.39 |
| ▸ | SLC1A2 | P43004 | 3/20 | 0.39 |
| ▸ | SLC1A1 | P43005 | 3/20 | 0.39 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.39 |
| ▸ | LTA4H | P09960 | 1/20 | 0.38 |
| ▸ | CTSK | P43235 | 3/20 | 0.38 |
| ▸ | CTSL | P07711 | 1/20 | 0.35 |
| ▸ | CTSB | P07858 | 1/20 | 0.35 |
| ▸ | CTSH | P09668 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24148724 | 0.84 | LMNA (0.45) | LMNAMETAP2SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL4765133 | 0.83 | ACACB (0.40) | PSMB5 | |
| SCHEMBL4765091 | 0.81 | CARM1 (0.39) | — | |
| SCHEMBL21671173 | 0.81 | LMNA (0.52) | LMNASLC1A3SLC1A2SLC1A1PSMB5 | |
| SCHEMBL2908890 | 0.81 | LMNA (0.52) | LMNASLC1A3SLC1A2SLC1A1PSMB5 | |
| SCHEMBL21671190 | 0.81 | LMNA (0.52) | LMNASLC1A3SLC1A2SLC1A1PSMB5 | |
| SCHEMBL3013492 | 0.79 | LMNA (0.50) | LMNAMETAP2SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL13057638 | 0.79 | LMNA (0.44) | LMNASLC1A3SLC1A2SLC1A1PSMB5 | |
| SCHEMBL26288580 | 0.79 | SCN9A (0.37) | — | |
| SCHEMBL8027411 | 0.79 | LMNA (0.48) | LMNASLC1A3SLC1A2SLC1A1PSMB5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8324179-B2 | Nucleoside analogs for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-7842672-B2 | Phosphonate inhibitors of HCV | GILEAD SCIENCES, INC. (US) | 2010-11-30 | — | — | US | disclosed |
| US-20100104532-A1 | NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2010-04-29 | — | — | US | disclosed |
| US-20080107628-A1 | Polymerase inhibitors | GILEAD SCIENCES, INC. | 2008-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080107628-A1 | Polymerase inhibitors | POLR2H, POLR2E, POLR1E | LMNA 1186/4885METAP2 767/4885SLC1A3 3413/4885 |
| US-20100104532-A1 | NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | SLC29A1, NUDT1, EIF2AK2 | LMNA 2301/4885METAP2 2064/4885SLC1A3 587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.